Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917075 | 0.94 | TLR7 (0.37) | TLR7TLR8 | |
| SCHEMBL21074153 | 0.94 | TLR7 (0.37) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL21074149 | 0.94 | TLR7 (0.37) | TLR7TLR8 | |
| SCHEMBL21074148 | 0.93 | TLR7 (0.37) | TLR7TLR8 | |
| SCHEMBL21074145 | 0.90 | TLR7 (0.38) | TLR7TLR8NUDT1 | |
| SCHEMBL2513263 | 0.84 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL1773748 | 0.83 | TLR7 (0.42) | TLR7TLR8NUDT1 | |
| SCHEMBL9979161 | 0.83 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL2514666 | 0.82 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL2520325 | 0.82 | TLR7 (0.42) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889158-B1 | FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3504215-B1 | FUSED [1,2]IMIDAZO[4,5-C]RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | 3M INNOVATIVE PROPERTIES CO (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3889158-A1 | FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | 3M Innovative Properties Company (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10414779-B2 | Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190194226-A1 | FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194226-A1 | FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | IFNG, IRF3, STING1 | TLR7 56/4885TLR8 232/4885NUDT1 519/4885 |
| US-10414779-B2 | Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups | IFNG, IRF3, STING1 | TLR7 56/4885TLR8 232/4885NUDT1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.